Company Filing History:
Years Active: 2000-2006
Title: Innovations in Antihypertensive Treatments by Inventor Anand Rao
Introduction
Anand Rao is an accomplished inventor based in Savage, MN (US), known for his significant contributions to the field of biotechnology. He holds a total of 3 patents that focus on the enzymatic treatment of whey proteins, particularly for the production of antihypertensive peptides. His work has the potential to impact the treatment of hypertension in both humans and domestic pets.
Latest Patents
Anand Rao's latest patents include groundbreaking research on the enzymatic treatment of whey proteins. One of his notable inventions involves the production of antihypertensive peptides through enzymatic digests of whey protein concentrates. The study revealed that the highest ACE-inhibitory activity was achieved with the purified peptide β-1g (f142–148), which was synthesized chemically, yielding an IC value of 0.04 mg powder/ml. Additionally, hydrolysates derived from BiPRO™ whey protein isolate and β-1g exhibited higher antihypertensive activities compared to other tested hydrolysates. These findings suggest that the recovered hydrolysate can be effectively used to treat hypertension in mammals, including humans and domestic pets such as dogs and cats.
Career Highlights
Throughout his career, Anand Rao has worked with prominent companies in the food industry, including Davisco Foods International, Inc. and Devisco Foods International, Inc. His expertise in enzymatic processes has positioned him as a key player in the development of innovative treatments for hypertension.
Collaborations
Anand has collaborated with notable professionals in his field, including Martin E. Davis and Sylvie Gauthier. Their combined efforts have contributed to the advancement of research in antihypertensive treatments.
Conclusion
Anand Rao's innovative work in the enzymatic treatment of whey proteins showcases his dedication to improving health outcomes for both humans and animals. His patents represent significant advancements in the field of biotechnology, particularly in the treatment of hypertension.